The US FDA has scheduled an Arthritis Advisory Committee (AAC) meeting for Tuesday, July 12, 2016, to discuss biologics license application 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.'s Humira (adalimumab), submitted by Amgen, Inc.
See the SAC Tracker report